Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.

Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.

Cancer. 2019 Aug 15;125(16):2772-2781. doi: 10.1002/cncr.32079. Epub 2019 Jun 2.

2.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Gut. 2019 Nov;68(11):1918-1927. doi: 10.1136/gutjnl-2018-317624. Epub 2019 Mar 9.

3.

Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue.

Medlow PW, Steele CJ, McCavigan AM, Reardon W, Brown CM, Lambe SM, Ishiy FAA, Walker SM, Logan GE, Raji OY, Berge V, Katz B, Kay EW, Sheehan K, Watson RW, Harkin DP, Kennedy RD, Knight LA.

BMC Med Genomics. 2018 Dec 27;11(1):125. doi: 10.1186/s12920-018-0442-y.

4.

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.

Campbell AM, Morris M, Gallagher R, Boyd R, Carson H, Harkin DP, Wielogorska E, Elliott C, Savage KI, McIntosh SA.

BMJ Open. 2018 Dec 22;8(12):e023115. doi: 10.1136/bmjopen-2018-023115.

5.

Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.

Bankhead P, Fernández JA, McArt DG, Boyle DP, Li G, Loughrey MB, Irwin GW, Harkin DP, James JA, McQuaid S, Salto-Tellez M, Hamilton PW.

Lab Invest. 2018 Jan;98(1):15-26. doi: 10.1038/labinvest.2017.131. Epub 2017 Dec 18.

6.

The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export.

Vohhodina J, Barros EM, Savage AL, Liberante FG, Manti L, Bankhead P, Cosgrove N, Madden AF, Harkin DP, Savage KI.

Nucleic Acids Res. 2017 Dec 15;45(22):12816-12833. doi: 10.1093/nar/gkx1046.

7.

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.

Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, Pang B, Logan GE, McCavigan AM, O'Rourke D, McArt DG, McDade SS, Mills IG, Prise KM, Knight LA, Steele CJ, Medlow PW, Berge V, Katz B, Loblaw DA, Harkin DP, James JA, O'Sullivan JM, Kennedy RD, Waugh DJ.

Ann Oncol. 2018 Jan 1;29(1):215-222. doi: 10.1093/annonc/mdx637.

8.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.

9.

Reply to L. Casadaban et al.

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2017 Apr 20;35(12):1373-1374. doi: 10.1200/JCO.2016.71.2646. Epub 2017 Jan 23. No abstract available.

PMID:
28113023
10.

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.

Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, McCloskey KD, Buckley NE, Savage KI, Salto-Tellez M, McQuaid S, Harte MT, Mullan PB, Harkin DP, Kennedy RD.

J Natl Cancer Inst. 2016 Oct 5;109(1). doi: 10.1093/jnci/djw199. Print 2017 Jan.

11.

The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription.

Johnston R, D'Costa Z, Ray S, Gorski J, Harkin DP, Mullan P, Panov KI.

Oncotarget. 2016 Oct 18;7(42):68097-68110. doi: 10.18632/oncotarget.11770.

12.

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.

13.

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.

Blayney JK, Davison T, McCabe N, Walker S, Keating K, Delaney T, Greenan C, Williams AR, McCluggage WG, Capes-Davis A, Harkin DP, Gourley C, Kennedy RD.

Nucleic Acids Res. 2016 Sep 30;44(17):e137. doi: 10.1093/nar/gkw578. Epub 2016 Jun 28.

14.

Dual roles of DNA repair enzymes in RNA biology/post-transcriptional control.

Vohhodina J, Harkin DP, Savage KI.

Wiley Interdiscip Rev RNA. 2016 Sep;7(5):604-19. doi: 10.1002/wrna.1353. Epub 2016 Apr 28. Review.

PMID:
27126972
15.

Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.

Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ.

Cancer. 2016 Mar 1;122(5):664-73. doi: 10.1002/cncr.29814. Epub 2015 Dec 22. No abstract available.

16.

Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention.

Buckley N, Boyle D, McArt D, Irwin G, Harkin DP, Lioe T, McQuaid S, James JA, Maxwell P, Hamilton P, Mullan PB, Salto-Tellez M.

Oncotarget. 2015 Dec 22;6(41):43244-54. doi: 10.18632/oncotarget.6525.

17.

Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.

McCabe N, Hanna C, Walker SM, Gonda D, Li J, Wikstrom K, Savage KI, Butterworth KT, Chen C, Harkin DP, Prise KM, Kennedy RD.

Cancer Res. 2015 Jun 1;75(11):2159-65. doi: 10.1158/0008-5472.CAN-14-3502. Epub 2015 Apr 13.

18.

PICan: An integromics framework for dynamic cancer biomarker discovery.

McArt DG, Blayney JK, Boyle DP, Irwin GW, Moran M, Hutchinson RA, Bankhead P, Kieran D, Wang Y, Dunne PD, Kennedy RD, Mullan PB, Harkin DP, Catherwood MA, James JA, Salto-Tellez M, Hamilton PW.

Mol Oncol. 2015 Jun;9(6):1234-40. doi: 10.1016/j.molonc.2015.02.002. Epub 2015 Mar 4.

19.

BRCA1, a 'complex' protein involved in the maintenance of genomic stability.

Savage KI, Harkin DP.

FEBS J. 2015 Feb;282(4):630-46. doi: 10.1111/febs.13150. Epub 2014 Dec 2. Review.

20.

Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression.

Stewart J, James J, McCluggage GW, McQuaid S, Arthur K, Boyle D, Mullan P, McArt D, Yan B, Irwin G, Harkin DP, Zhengdeng L, Ong CW, Yu J, Virshup DM, Salto-Tellez M.

Mod Pathol. 2015 Mar;28(3):428-36. doi: 10.1038/modpathol.2014.114. Epub 2014 Sep 26.

21.

Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability.

Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L, Powell AJ, Pellagatti A, Lukashchuk N, McCance DJ, McCluggage WG, Schettino G, Salto-Tellez M, Boultwood J, Richard DJ, McDade SS, Harkin DP.

Mol Cell. 2014 May 8;54(3):445-59. doi: 10.1016/j.molcel.2014.03.021. Epub 2014 Apr 17.

22.

TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.

D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, Murray JT, Kennedy RD, Mulligan KA, Harkin DP, Waugh DJ, Scott CJ, Salto-Tellez M, Williams R, Mullan PB.

Oncotarget. 2014 Mar 30;5(6):1609-20.

23.

BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability.

Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkin DP.

Cancer Res. 2014 May 15;74(10):2773-2784. doi: 10.1158/0008-5472.CAN-13-2611. Epub 2014 Mar 17.

24.

The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer.

Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, Catherwood MA, Harkin DP, Salto-Tellez M.

Histopathology. 2014 Sep;65(3):340-52. doi: 10.1111/his.12398. Epub 2014 Apr 16.

PMID:
24612173
25.

Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data.

Ahdesmäki M, Lancashire L, Proutski V, Wilson C, Davison TS, Harkin DP, Kennedy RD.

Stat Appl Genet Mol Biol. 2013 Oct 1;12(5):619-35. doi: 10.1515/sagmb-2012-0047.

PMID:
24077567
26.

BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.

Buckley NE, Nic An tSaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.

Nucleic Acids Res. 2013 Oct;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.

27.

NF-κB is a critical mediator of BRCA1-induced chemoresistance.

Harte MT, Gorski JJ, Savage KI, Purcell JW, Barros EM, Burn PM, McFarlane C, Mullan PB, Kennedy RD, Perkins ND, Harkin DP.

Oncogene. 2014 Feb 6;33(6):713-723. doi: 10.1038/onc.2013.10. Epub 2013 Feb 25.

28.

Implications for powering biomarker discovery studies.

Dibben SM, Holt RJ, Davison TS, Wilson CL, Taylor J, Paul I, McManus K, Kelly PJ, Proutski V, Harkin DP, Kerr P, Fennell DA, James JA, Kennedy RD.

J Mol Diagn. 2012 Mar-Apr;14(2):130-9. doi: 10.1016/j.jmoldx.2011.10.002. Epub 2012 Jan 15.

PMID:
22251612
29.

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

Busacca S, Sheaff M, Arthur K, Gray SG, O'Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2012 Jun;227(2):200-8. doi: 10.1002/path.3979. Epub 2012 Mar 19.

PMID:
22190288
30.

BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.

Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, Harkin DP, Mullan PB.

Oncogene. 2012 Aug 9;31(32):3667-78. doi: 10.1038/onc.2011.531. Epub 2011 Nov 28.

PMID:
22120723
31.

Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.

Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, Holt RJ, Proutski V, Ahdesmaki M, Farztdinov V, Goffard N, Hey P, McDyer F, Mulligan K, Mussen J, O'Brien E, Oliver G, Walker SM, Mulligan JM, Wilson C, Winter A, O'Donoghue D, Mulcahy H, O'Sullivan J, Sheahan K, Hyland J, Dhir R, Bathe OF, Winqvist O, Manne U, Shanmugam C, Ramaswamy S, Leon EJ, Smith WI Jr, McDermott U, Wilson RH, Longley D, Marshall J, Cummins R, Sargent DJ, Johnston PG, Harkin DP.

J Clin Oncol. 2011 Dec 10;29(35):4620-6. doi: 10.1200/JCO.2011.35.4498. Epub 2011 Nov 7.

PMID:
22067406
32.

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, Maxwell P, Lamers E, Lioe TF, Williams AR, Kennedy RD, Gourley C, Harkin DP.

Gynecol Oncol. 2011 Dec;123(3):492-8. doi: 10.1016/j.ygyno.2011.08.017. Epub 2011 Sep 13.

PMID:
21920589
33.

Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis.

Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney JK, Ge Z, Harkin DP.

Nucleic Acids Res. 2011 Dec;39(22):9536-48. doi: 10.1093/nar/gkr679. Epub 2011 Aug 31.

34.

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.

Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27.

PMID:
21706479
35.

The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.

Buckley NE, Conlon SJ, Jirstrom K, Kay EW, Crawford NT, O'Grady A, Sheehan K, Mc Dade SS, Wang CW, McCance DJ, Johnston PG, Kennedy RD, Harkin DP, Mullan PB.

Cancer Res. 2011 Mar 1;71(5):1933-44. doi: 10.1158/0008-5472.CAN-10-2717.

36.

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.

El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS.

Cancer Sci. 2010 Jun;101(6):1354-60. doi: 10.1111/j.1349-7006.2010.01561.x. Epub 2010 Mar 10.

37.

Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.

Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A.

Oncologist. 2010;15(4):390-404. doi: 10.1634/theoncologist.2009-0233. Epub 2010 Mar 29. Review.

38.

T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells.

Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP, Mullan PB.

Oncogene. 2010 Jun 3;29(22):3252-62. doi: 10.1038/onc.2010.84. Epub 2010 Mar 29.

PMID:
20348948
39.

BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription.

Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, Mullan PB, Harkin DP.

Cancer Res. 2010 Mar 15;70(6):2538-47. doi: 10.1158/0008-5472.CAN-09-2089. Epub 2010 Mar 9.

40.

BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.

Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, McDyer FA, Kennedy RD, Wilson RH, Mullan PB, Harkin DP.

Breast Cancer Res Treat. 2010 Aug;122(3):721-31. doi: 10.1007/s10549-009-0565-0. Epub 2009 Oct 31.

PMID:
19882246
41.

The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.

Gorski JJ, Kennedy RD, Hosey AM, Harkin DP.

Clin Cancer Res. 2009 Mar 1;15(5):1514-8. doi: 10.1158/1078-0432.CCR-08-0640. Epub 2009 Feb 17. Review.

42.

BRCA1 and implications for response to chemotherapy in ovarian cancer.

Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP.

Gynecol Oncol. 2009 Apr;113(1):134-42. doi: 10.1016/j.ygyno.2008.12.015. Epub 2009 Jan 24. Review.

PMID:
19168207
43.

Generation of a non-small cell lung cancer transcriptome microarray.

Tanney A, Oliver GR, Farztdinov V, Kennedy RD, Mulligan JM, Fulton CE, Farragher SM, Field JK, Johnston PG, Harkin DP, Proutski V, Mulligan KA.

BMC Med Genomics. 2008 May 30;1:20. doi: 10.1186/1755-8794-1-20.

44.

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.

Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP.

Clin Cancer Res. 2007 Dec 15;13(24):7413-20.

45.

Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP.

J Natl Cancer Inst. 2007 Nov 21;99(22):1683-94. Epub 2007 Nov 13.

46.

Role played by BRCA1 in transcriptional regulation in response to therapy.

Murray MM, Mullan PB, Harkin DP.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1342-6. Review.

PMID:
17956347
47.

BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.

Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP, Mullan PB.

Mol Cancer Res. 2007 Mar;5(3):261-70.

48.

BRCA1, a potential predictive biomarker in the treatment of breast cancer.

James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP.

Oncologist. 2007 Feb;12(2):142-50. Review.

49.
50.

The role of BRCA1 in transcriptional regulation and cell cycle control.

Mullan PB, Quinn JE, Harkin DP.

Oncogene. 2006 Sep 25;25(43):5854-63. Review.

PMID:
16998500

Supplemental Content

Loading ...
Support Center